Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-102 in acute schizophrenia
NCT06179108Phase 2Completed
- Sponsor
- LB Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- T-cell Engagers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LP-102 in schizophrenia (4 arms), sponsored by LB Pharmaceuticals. Primary endpoint: Positive and Negative Syndrome Scale Total at 28 days. Started Nov 2023; status: completed.
02
Drugs
LP-102
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06179108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179108.